TrialBMC medicine2022

Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial.

Xiaojian Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.